New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2013
07:31 EDTTXMDTherapeuticsMD receives notice of allowance for patent
TherapeuticsMD received a Notice of Allowance from the U.S. Patent and Trademark Office pertaining to its U.S. Patent Application 13/684,002 - "Natural Combination Hormone Replacement Formulations and Therapies." This Patent Application covers the company’s platform technology TX 12-001-HR, its oral bioidentical 17β-estradiol and progesterone combination drug candidate. Robert Finizio, CEO and Co-founder of TherapeuticsMD, says "Based on clinical data presented earlier this year, we believe TX 12-001-HR has overcome these hurdles and that this novel combination of 17ß- estradiol and progesterone may achieve equivalent efficacy with better bioavailability as compared to current hormone therapies. We eagerly await the outcomes of the ongoing REPLENISH Trial."
News For TXMD From The Last 14 Days
Check below for free stories on TXMD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for TXMD

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use